cefminox

{{cs1 config|name-list-style=vanc}}

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 444377781

| IUPAC_name = (6R,7S)-7-(((((2S)-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid

| image = Cefminox.svg

| width = 280

| tradename =

| Drugs.com = {{drugs.com|international|cefminox}}

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Rx-only

| routes_of_administration = IM, IV

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 84305-41-9

| ATC_prefix = J01

| ATC_suffix = DC12

| ATC_supplemental =

| ChEBI = 135817

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1276342

| PubChem = 71141

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = PW08Y13465

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D07642

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 64286

| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSC[C@H](C(=O)O)N)CSc3nnnn3C)C(=O)O

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI = 1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = JSDXOWVAHXDYCU-VXSYNFHWSA-N

| chemical_formula =

| C=16 | H=21 | N=7 | O=7 | S=3

}}

Cefminox (INN) is a second-generation cephalosporin antibiotic.{{cite journal | vauthors = Torres AJ, Valladares LD, Jover JM, Sánchez-Pernaute A, Frías J, Carcas AJ, Coronel P, Ródenas E, Pérez-Balcabao I, Fernández-Roblas R, Moreno M, Balibrea JL | display-authors = 6 | title = Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial | journal = Infection | volume = 28 | issue = 5 | pages = 318–22 | date = September 2000 | pmid = 11073141 | doi = 10.1007/s150100070027 | s2cid = 41555982 }}{{cite patent | country = US | number = 8497086 | title = Reaction Medium For Methicillin-Resistant Staphylococcus Aureus (MRSA) Bacteria | assign1 = Biomereux | gdate = 20 July 2013 }}